

PHEBRA CANADA'S MILESTONES IN DELIVERY OF CRITICAL MEDICINES

Australian pharmaceutical group Phebra (the 'Company') said today the successful Canadian launch and distribution of its Arsenic Trioxide Injection for the treatment of the rare haematological disease Acute Promyelocytic Leukaemia (APL) and upcoming product launches, demonstrates the Company's ability to deliver new and existing critical care injectables into the growing North American market, through its subsidiary Phebra Canada.

Phebra Canada has reached a number of milestones including its assistance in securing critical supplies of Phebra's product portfolio for Health Canada during this COVID crisis.

The Vice President of Phebra's North America operations, Tony Romagnino, said drugs manufactured in Australia and distributed in Canada, came at just the right time for Canadian patients.

"Phebra Canada has established relationships at every level of the supply chain. From clinicians to pharmacists to hospital purchasing groups, wholesalers and Provincial and Federal stakeholders – all of them have been working with Phebra Canada to address shortages and patient needs," Mr Romagnino said.

Mr Romagnino said Phebra Canada is now planning for the launch of another Australian-made and supplied product, the Methylene Blue Injection, which is mainly used in a range of diagnostic procedures such as fistula detection and for the delineation of certain body tissues during surgery. It is due to be launched in Canada in June, 2021.

"We've been extremely pleased with the steady supply of critical care injectables into the Canadian market to date and we are actively pursuing future critical care products which focus on the treatment of rare diseases," Mr Romagnino said.

"Phebra Canada brings a type of health care supply based on compassion and we look forward to continuing our work with Canadian health authorities and key opinion leaders to deliver therapies that save and improve the lives of people across communities in Canada."

Phebra Group CEO, Andre Vlok, said the Company's expertise in drug development and manufacturing at Phebra's expanded multi-purpose sterile injectables plant at Lane Cove West in Sydney, combined with its strong international supply chain, provides the platform for Phebra Canada's ongoing progress.

"We have invested in new state-of-the-art manufacturing capability, including robotic equipment and bolstered our capacity to supply greater quantities of Phebra products into Canada and other overseas markets. We are committed to our international expansion program," Mr Vlok explained.



About Phebra Group

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

At Phebra, we create critical medicines that save and improve lives.

Phebra Group Media Contact: Richard Lenarduzzi +61 411 254 390